http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 22 Jul 2026 01:00:18 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Mergers+and+Acquisitions/Ipsen+completes+acquisition+of+Memo+Therapeutics+AG/26796983.html <p>Ipsen (Euronext: IPN; ADR: IPSEY) has completed its acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, a monoclonal antibody targeting BK polyomavirus (BKPyV) reactivation in kidney transplant recipients.</p> <p>Potravitug is designed to address BKPyV reactivation, a condition with no currently approved targeted therapies. The drug candidate showed results in the Phase II SAFE KIDNEY II trial, described as the largest placebo-controlled study conducted in this patient population, with findings including an anti-viral response and resolution of BKPyV-associated nephropathy.</p> <p>BKPyV is a virus that commonly remains dormant but can reactivate in immunocompromised individuals, including kidney transplant recipients taking anti-rejection http://www.streetinsider.com/Mergers+and+Acquisitions/Ipsen+completes+acquisition+of+Memo+Therapeutics+AG/26796983.html Wed, 22 Jul 2026 01:00:18 -0400 A.00204076 A.18335591 A.31979641 IPN IPSEY O.00323532 O.00374663 O.04960887 O.14731247 http://www.streetinsider.com/Mergers+and+Acquisitions/Ipsen+completes+acquisition+of+Memo+Therapeutics+AG/26796983.html <p>Ipsen (Euronext: IPN; ADR: IPSEY) has completed its acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, a monoclonal antibody targeting BK polyomavirus (BKPyV) reactivation in kidney transplant recipients.</p> <p>Potravitug is designed to address BKPyV reactivation, a condition with no currently approved targeted therapies. The drug candidate showed results in the Phase II SAFE KIDNEY II trial, described as the largest placebo-controlled study conducted in this patient population, with findings including an anti-viral response and resolution of BKPyV-associated nephropathy.</p> <p>BKPyV is a virus that commonly remains dormant but can reactivate in immunocompromised individuals, including kidney transplant recipients taking anti-rejection http://www.streetinsider.com/Mergers+and+Acquisitions/Ipsen+completes+acquisition+of+Memo+Therapeutics+AG/26796983.html Wed, 22 Jul 2026 01:00:18 -0400 A.00204076 A.18335591 A.31979641 IPN IPSEY O.00323532 O.00374663 O.04960887 O.14731247 http://www.streetinsider.com/Mergers+and+Acquisitions/Ipsen+completes+acquisition+of+Memo+Therapeutics+AG/26796983.html <p>Ipsen (Euronext: IPN; ADR: IPSEY) has completed its acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, a monoclonal antibody targeting BK polyomavirus (BKPyV) reactivation in kidney transplant recipients.</p> <p>Potravitug is designed to address BKPyV reactivation, a condition with no currently approved targeted therapies. The drug candidate showed results in the Phase II SAFE KIDNEY II trial, described as the largest placebo-controlled study conducted in this patient population, with findings including an anti-viral response and resolution of BKPyV-associated nephropathy.</p> <p>BKPyV is a virus that commonly remains dormant but can reactivate in immunocompromised individuals, including kidney transplant recipients taking anti-rejection http://www.streetinsider.com/Mergers+and+Acquisitions/Ipsen+completes+acquisition+of+Memo+Therapeutics+AG/26796983.html Wed, 22 Jul 2026 01:00:18 -0400 A.00204076 A.18335591 A.31979641 IPN IPSEY O.00323532 O.00374663 O.04960887 O.14731247 http://www.streetinsider.com/Mergers+and+Acquisitions/Ipsen+completes+acquisition+of+Memo+Therapeutics+AG/26796983.html <p>Ipsen (Euronext: IPN; ADR: IPSEY) has completed its acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, a monoclonal antibody targeting BK polyomavirus (BKPyV) reactivation in kidney transplant recipients.</p> <p>Potravitug is designed to address BKPyV reactivation, a condition with no currently approved targeted therapies. The drug candidate showed results in the Phase II SAFE KIDNEY II trial, described as the largest placebo-controlled study conducted in this patient population, with findings including an anti-viral response and resolution of BKPyV-associated nephropathy.</p> <p>BKPyV is a virus that commonly remains dormant but can reactivate in immunocompromised individuals, including kidney transplant recipients taking anti-rejection http://www.streetinsider.com/Mergers+and+Acquisitions/Ipsen+completes+acquisition+of+Memo+Therapeutics+AG/26796983.html Wed, 22 Jul 2026 01:00:18 -0400 A.00204076 A.18335591 A.31979641 IPN IPSEY O.00323532 O.00374663 O.04960887 O.14731247 http://www.streetinsider.com/Mergers+and+Acquisitions/Ipsen+completes+acquisition+of+Memo+Therapeutics+AG/26796983.html <p>Ipsen (Euronext: IPN; ADR: IPSEY) has completed its acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, a monoclonal antibody targeting BK polyomavirus (BKPyV) reactivation in kidney transplant recipients.</p> <p>Potravitug is designed to address BKPyV reactivation, a condition with no currently approved targeted therapies. The drug candidate showed results in the Phase II SAFE KIDNEY II trial, described as the largest placebo-controlled study conducted in this patient population, with findings including an anti-viral response and resolution of BKPyV-associated nephropathy.</p> <p>BKPyV is a virus that commonly remains dormant but can reactivate in immunocompromised individuals, including kidney transplant recipients taking anti-rejection http://www.streetinsider.com/Mergers+and+Acquisitions/Ipsen+completes+acquisition+of+Memo+Therapeutics+AG/26796983.html Wed, 22 Jul 2026 01:00:18 -0400 A.00204076 A.18335591 A.31979641 IPN IPSEY O.00323532 O.00374663 O.04960887 O.14731247 http://www.streetinsider.com/Mergers+and+Acquisitions/Ipsen+completes+acquisition+of+Memo+Therapeutics+AG/26796983.html <p>Ipsen (Euronext: IPN; ADR: IPSEY) has completed its acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, a monoclonal antibody targeting BK polyomavirus (BKPyV) reactivation in kidney transplant recipients.</p> <p>Potravitug is designed to address BKPyV reactivation, a condition with no currently approved targeted therapies. The drug candidate showed results in the Phase II SAFE KIDNEY II trial, described as the largest placebo-controlled study conducted in this patient population, with findings including an anti-viral response and resolution of BKPyV-associated nephropathy.</p> <p>BKPyV is a virus that commonly remains dormant but can reactivate in immunocompromised individuals, including kidney transplant recipients taking anti-rejection http://www.streetinsider.com/Mergers+and+Acquisitions/Ipsen+completes+acquisition+of+Memo+Therapeutics+AG/26796983.html Wed, 22 Jul 2026 01:00:18 -0400 A.00204076 A.18335591 A.31979641 IPN IPSEY O.00323532 O.00374663 O.04960887 O.14731247 http://www.streetinsider.com/Mergers+and+Acquisitions/Ipsen+completes+acquisition+of+Memo+Therapeutics+AG/26796983.html <p>Ipsen (Euronext: IPN; ADR: IPSEY) has completed its acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, a monoclonal antibody targeting BK polyomavirus (BKPyV) reactivation in kidney transplant recipients.</p> <p>Potravitug is designed to address BKPyV reactivation, a condition with no currently approved targeted therapies. The drug candidate showed results in the Phase II SAFE KIDNEY II trial, described as the largest placebo-controlled study conducted in this patient population, with findings including an anti-viral response and resolution of BKPyV-associated nephropathy.</p> <p>BKPyV is a virus that commonly remains dormant but can reactivate in immunocompromised individuals, including kidney transplant recipients taking anti-rejection http://www.streetinsider.com/Mergers+and+Acquisitions/Ipsen+completes+acquisition+of+Memo+Therapeutics+AG/26796983.html Wed, 22 Jul 2026 01:00:18 -0400 A.00204076 A.18335591 A.31979641 IPN IPSEY O.00323532 O.00374663 O.04960887 O.14731247 http://www.streetinsider.com/Mergers+and+Acquisitions/Ipsen+completes+acquisition+of+Memo+Therapeutics+AG/26796983.html <p>Ipsen (Euronext: IPN; ADR: IPSEY) has completed its acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, a monoclonal antibody targeting BK polyomavirus (BKPyV) reactivation in kidney transplant recipients.</p> <p>Potravitug is designed to address BKPyV reactivation, a condition with no currently approved targeted therapies. The drug candidate showed results in the Phase II SAFE KIDNEY II trial, described as the largest placebo-controlled study conducted in this patient population, with findings including an anti-viral response and resolution of BKPyV-associated nephropathy.</p> <p>BKPyV is a virus that commonly remains dormant but can reactivate in immunocompromised individuals, including kidney transplant recipients taking anti-rejection http://www.streetinsider.com/Mergers+and+Acquisitions/Ipsen+completes+acquisition+of+Memo+Therapeutics+AG/26796983.html Wed, 22 Jul 2026 01:00:18 -0400 A.00204076 A.18335591 A.31979641 IPN IPSEY O.00323532 O.00374663 O.04960887 O.14731247 http://www.streetinsider.com/Mergers+and+Acquisitions/Ipsen+completes+acquisition+of+Memo+Therapeutics+AG/26796983.html <p>Ipsen (Euronext: IPN; ADR: IPSEY) has completed its acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, a monoclonal antibody targeting BK polyomavirus (BKPyV) reactivation in kidney transplant recipients.</p> <p>Potravitug is designed to address BKPyV reactivation, a condition with no currently approved targeted therapies. The drug candidate showed results in the Phase II SAFE KIDNEY II trial, described as the largest placebo-controlled study conducted in this patient population, with findings including an anti-viral response and resolution of BKPyV-associated nephropathy.</p> <p>BKPyV is a virus that commonly remains dormant but can reactivate in immunocompromised individuals, including kidney transplant recipients taking anti-rejection http://www.streetinsider.com/Mergers+and+Acquisitions/Ipsen+completes+acquisition+of+Memo+Therapeutics+AG/26796983.html Wed, 22 Jul 2026 01:00:18 -0400 A.00204076 A.18335591 A.31979641 IPN IPSEY O.00323532 O.00374663 O.04960887 O.14731247 http://www.streetinsider.com/FDA/Ipsen+completes+acquisition+of+Memo+Therapeutics+AG/26796983.html <p>Ipsen (Euronext: IPN; ADR: IPSEY) has completed its acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, a monoclonal antibody targeting BK polyomavirus (BKPyV) reactivation in kidney transplant recipients.</p> <p>Potravitug is designed to address BKPyV reactivation, a condition with no currently approved targeted therapies. The drug candidate showed results in the Phase II SAFE KIDNEY II trial, described as the largest placebo-controlled study conducted in this patient population, with findings including an anti-viral response and resolution of BKPyV-associated nephropathy.</p> <p>BKPyV is a virus that commonly remains dormant but can reactivate in immunocompromised individuals, including kidney transplant recipients taking anti-rejection http://www.streetinsider.com/FDA/Ipsen+completes+acquisition+of+Memo+Therapeutics+AG/26796983.html Wed, 22 Jul 2026 01:00:18 -0400 A.00204076 A.18335591 A.31979641 IPN IPSEY O.00323532 O.00374663 O.04960887 O.14731247 http://www.streetinsider.com/FDA/Ipsen+completes+acquisition+of+Memo+Therapeutics+AG/26796983.html <p>Ipsen (Euronext: IPN; ADR: IPSEY) has completed its acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, a monoclonal antibody targeting BK polyomavirus (BKPyV) reactivation in kidney transplant recipients.</p> <p>Potravitug is designed to address BKPyV reactivation, a condition with no currently approved targeted therapies. The drug candidate showed results in the Phase II SAFE KIDNEY II trial, described as the largest placebo-controlled study conducted in this patient population, with findings including an anti-viral response and resolution of BKPyV-associated nephropathy.</p> <p>BKPyV is a virus that commonly remains dormant but can reactivate in immunocompromised individuals, including kidney transplant recipients taking anti-rejection http://www.streetinsider.com/FDA/Ipsen+completes+acquisition+of+Memo+Therapeutics+AG/26796983.html Wed, 22 Jul 2026 01:00:18 -0400 A.00204076 A.18335591 A.31979641 IPN IPSEY O.00323532 O.00374663 O.04960887 O.14731247 http://www.streetinsider.com/FDA/Ipsen+completes+acquisition+of+Memo+Therapeutics+AG/26796983.html <p>Ipsen (Euronext: IPN; ADR: IPSEY) has completed its acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, a monoclonal antibody targeting BK polyomavirus (BKPyV) reactivation in kidney transplant recipients.</p> <p>Potravitug is designed to address BKPyV reactivation, a condition with no currently approved targeted therapies. The drug candidate showed results in the Phase II SAFE KIDNEY II trial, described as the largest placebo-controlled study conducted in this patient population, with findings including an anti-viral response and resolution of BKPyV-associated nephropathy.</p> <p>BKPyV is a virus that commonly remains dormant but can reactivate in immunocompromised individuals, including kidney transplant recipients taking anti-rejection http://www.streetinsider.com/FDA/Ipsen+completes+acquisition+of+Memo+Therapeutics+AG/26796983.html Wed, 22 Jul 2026 01:00:18 -0400 A.00204076 A.18335591 A.31979641 IPN IPSEY O.00323532 O.00374663 O.04960887 O.14731247 http://www.streetinsider.com/FDA/Ipsen+completes+acquisition+of+Memo+Therapeutics+AG/26796983.html <p>Ipsen (Euronext: IPN; ADR: IPSEY) has completed its acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, a monoclonal antibody targeting BK polyomavirus (BKPyV) reactivation in kidney transplant recipients.</p> <p>Potravitug is designed to address BKPyV reactivation, a condition with no currently approved targeted therapies. The drug candidate showed results in the Phase II SAFE KIDNEY II trial, described as the largest placebo-controlled study conducted in this patient population, with findings including an anti-viral response and resolution of BKPyV-associated nephropathy.</p> <p>BKPyV is a virus that commonly remains dormant but can reactivate in immunocompromised individuals, including kidney transplant recipients taking anti-rejection http://www.streetinsider.com/FDA/Ipsen+completes+acquisition+of+Memo+Therapeutics+AG/26796983.html Wed, 22 Jul 2026 01:00:18 -0400 A.00204076 A.18335591 A.31979641 IPN IPSEY O.00323532 O.00374663 O.04960887 O.14731247 http://www.streetinsider.com/FDA/Ipsen+completes+acquisition+of+Memo+Therapeutics+AG/26796983.html <p>Ipsen (Euronext: IPN; ADR: IPSEY) has completed its acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, a monoclonal antibody targeting BK polyomavirus (BKPyV) reactivation in kidney transplant recipients.</p> <p>Potravitug is designed to address BKPyV reactivation, a condition with no currently approved targeted therapies. The drug candidate showed results in the Phase II SAFE KIDNEY II trial, described as the largest placebo-controlled study conducted in this patient population, with findings including an anti-viral response and resolution of BKPyV-associated nephropathy.</p> <p>BKPyV is a virus that commonly remains dormant but can reactivate in immunocompromised individuals, including kidney transplant recipients taking anti-rejection http://www.streetinsider.com/FDA/Ipsen+completes+acquisition+of+Memo+Therapeutics+AG/26796983.html Wed, 22 Jul 2026 01:00:18 -0400 A.00204076 A.18335591 A.31979641 IPN IPSEY O.00323532 O.00374663 O.04960887 O.14731247 http://www.streetinsider.com/FDA/Ipsen+completes+acquisition+of+Memo+Therapeutics+AG/26796983.html <p>Ipsen (Euronext: IPN; ADR: IPSEY) has completed its acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, a monoclonal antibody targeting BK polyomavirus (BKPyV) reactivation in kidney transplant recipients.</p> <p>Potravitug is designed to address BKPyV reactivation, a condition with no currently approved targeted therapies. The drug candidate showed results in the Phase II SAFE KIDNEY II trial, described as the largest placebo-controlled study conducted in this patient population, with findings including an anti-viral response and resolution of BKPyV-associated nephropathy.</p> <p>BKPyV is a virus that commonly remains dormant but can reactivate in immunocompromised individuals, including kidney transplant recipients taking anti-rejection http://www.streetinsider.com/FDA/Ipsen+completes+acquisition+of+Memo+Therapeutics+AG/26796983.html Wed, 22 Jul 2026 01:00:18 -0400 A.00204076 A.18335591 A.31979641 IPN IPSEY O.00323532 O.00374663 O.04960887 O.14731247 http://www.streetinsider.com/FDA/Ipsen+completes+acquisition+of+Memo+Therapeutics+AG/26796983.html <p>Ipsen (Euronext: IPN; ADR: IPSEY) has completed its acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, a monoclonal antibody targeting BK polyomavirus (BKPyV) reactivation in kidney transplant recipients.</p> <p>Potravitug is designed to address BKPyV reactivation, a condition with no currently approved targeted therapies. The drug candidate showed results in the Phase II SAFE KIDNEY II trial, described as the largest placebo-controlled study conducted in this patient population, with findings including an anti-viral response and resolution of BKPyV-associated nephropathy.</p> <p>BKPyV is a virus that commonly remains dormant but can reactivate in immunocompromised individuals, including kidney transplant recipients taking anti-rejection http://www.streetinsider.com/FDA/Ipsen+completes+acquisition+of+Memo+Therapeutics+AG/26796983.html Wed, 22 Jul 2026 01:00:18 -0400 A.00204076 A.18335591 A.31979641 IPN IPSEY O.00323532 O.00374663 O.04960887 O.14731247 http://www.streetinsider.com/FDA/Ipsen+completes+acquisition+of+Memo+Therapeutics+AG/26796983.html <p>Ipsen (Euronext: IPN; ADR: IPSEY) has completed its acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, a monoclonal antibody targeting BK polyomavirus (BKPyV) reactivation in kidney transplant recipients.</p> <p>Potravitug is designed to address BKPyV reactivation, a condition with no currently approved targeted therapies. The drug candidate showed results in the Phase II SAFE KIDNEY II trial, described as the largest placebo-controlled study conducted in this patient population, with findings including an anti-viral response and resolution of BKPyV-associated nephropathy.</p> <p>BKPyV is a virus that commonly remains dormant but can reactivate in immunocompromised individuals, including kidney transplant recipients taking anti-rejection http://www.streetinsider.com/FDA/Ipsen+completes+acquisition+of+Memo+Therapeutics+AG/26796983.html Wed, 22 Jul 2026 01:00:18 -0400 A.00204076 A.18335591 A.31979641 IPN IPSEY O.00323532 O.00374663 O.04960887 O.14731247 http://www.streetinsider.com/FDA/Ipsen+completes+acquisition+of+Memo+Therapeutics+AG/26796983.html <p>Ipsen (Euronext: IPN; ADR: IPSEY) has completed its acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, a monoclonal antibody targeting BK polyomavirus (BKPyV) reactivation in kidney transplant recipients.</p> <p>Potravitug is designed to address BKPyV reactivation, a condition with no currently approved targeted therapies. The drug candidate showed results in the Phase II SAFE KIDNEY II trial, described as the largest placebo-controlled study conducted in this patient population, with findings including an anti-viral response and resolution of BKPyV-associated nephropathy.</p> <p>BKPyV is a virus that commonly remains dormant but can reactivate in immunocompromised individuals, including kidney transplant recipients taking anti-rejection http://www.streetinsider.com/FDA/Ipsen+completes+acquisition+of+Memo+Therapeutics+AG/26796983.html Wed, 22 Jul 2026 01:00:18 -0400 A.00204076 A.18335591 A.31979641 IPN IPSEY O.00323532 O.00374663 O.04960887 O.14731247 http://www.streetinsider.com/Mergers+and+Acquisitions/Ipsen+acquires+Memo+Therapeutics%2C+adding+kidney+transplant+drug/26796982.html <p>Ipsen (Euronext: IPN; ADR: IPSEY) has completed its acquisition of Memo Therapeutics AG, a late-stage biotech company developing potravitug, a monoclonal antibody targeting BK polyomavirus reactivation in kidney transplant recipients, according to a press release from the Paris-based company.</p> <p>Potravitug is described as a monoclonal antibody targeting BK polyomavirus (BKPyV) reactivation in kidney transplant recipients. The drug has been evaluated in the Phase II SAFE KIDNEY II trial, which the company says is the largest placebo-controlled study conducted in this patient population. The trial showed an anti-viral response and resolution of BKPyV-associated nephropathy.</p> <p>BKPyV is a virus that can reactivate in immunocompromised http://www.streetinsider.com/Mergers+and+Acquisitions/Ipsen+acquires+Memo+Therapeutics%2C+adding+kidney+transplant+drug/26796982.html Wed, 22 Jul 2026 01:00:14 -0400 A.00204076 A.18335591 A.31979641 IPN IPSEY O.00323532 O.00374663 O.04960887 O.14731247 http://www.streetinsider.com/Mergers+and+Acquisitions/Ipsen+acquires+Memo+Therapeutics%2C+adding+kidney+transplant+drug/26796982.html <p>Ipsen (Euronext: IPN; ADR: IPSEY) has completed its acquisition of Memo Therapeutics AG, a late-stage biotech company developing potravitug, a monoclonal antibody targeting BK polyomavirus reactivation in kidney transplant recipients, according to a press release from the Paris-based company.</p> <p>Potravitug is described as a monoclonal antibody targeting BK polyomavirus (BKPyV) reactivation in kidney transplant recipients. The drug has been evaluated in the Phase II SAFE KIDNEY II trial, which the company says is the largest placebo-controlled study conducted in this patient population. The trial showed an anti-viral response and resolution of BKPyV-associated nephropathy.</p> <p>BKPyV is a virus that can reactivate in immunocompromised http://www.streetinsider.com/Mergers+and+Acquisitions/Ipsen+acquires+Memo+Therapeutics%2C+adding+kidney+transplant+drug/26796982.html Wed, 22 Jul 2026 01:00:14 -0400 A.00204076 A.18335591 A.31979641 IPN IPSEY O.00323532 O.00374663 O.04960887 O.14731247 http://www.streetinsider.com/Mergers+and+Acquisitions/Ipsen+acquires+Memo+Therapeutics%2C+adding+kidney+transplant+drug/26796982.html <p>Ipsen (Euronext: IPN; ADR: IPSEY) has completed its acquisition of Memo Therapeutics AG, a late-stage biotech company developing potravitug, a monoclonal antibody targeting BK polyomavirus reactivation in kidney transplant recipients, according to a press release from the Paris-based company.</p> <p>Potravitug is described as a monoclonal antibody targeting BK polyomavirus (BKPyV) reactivation in kidney transplant recipients. The drug has been evaluated in the Phase II SAFE KIDNEY II trial, which the company says is the largest placebo-controlled study conducted in this patient population. The trial showed an anti-viral response and resolution of BKPyV-associated nephropathy.</p> <p>BKPyV is a virus that can reactivate in immunocompromised http://www.streetinsider.com/Mergers+and+Acquisitions/Ipsen+acquires+Memo+Therapeutics%2C+adding+kidney+transplant+drug/26796982.html Wed, 22 Jul 2026 01:00:14 -0400 A.00204076 A.18335591 A.31979641 IPN IPSEY O.00323532 O.00374663 O.04960887 O.14731247 http://www.streetinsider.com/Mergers+and+Acquisitions/Ipsen+acquires+Memo+Therapeutics%2C+adding+kidney+transplant+drug/26796982.html <p>Ipsen (Euronext: IPN; ADR: IPSEY) has completed its acquisition of Memo Therapeutics AG, a late-stage biotech company developing potravitug, a monoclonal antibody targeting BK polyomavirus reactivation in kidney transplant recipients, according to a press release from the Paris-based company.</p> <p>Potravitug is described as a monoclonal antibody targeting BK polyomavirus (BKPyV) reactivation in kidney transplant recipients. The drug has been evaluated in the Phase II SAFE KIDNEY II trial, which the company says is the largest placebo-controlled study conducted in this patient population. The trial showed an anti-viral response and resolution of BKPyV-associated nephropathy.</p> <p>BKPyV is a virus that can reactivate in immunocompromised http://www.streetinsider.com/Mergers+and+Acquisitions/Ipsen+acquires+Memo+Therapeutics%2C+adding+kidney+transplant+drug/26796982.html Wed, 22 Jul 2026 01:00:14 -0400 A.00204076 A.18335591 A.31979641 IPN IPSEY O.00323532 O.00374663 O.04960887 O.14731247 http://www.streetinsider.com/Mergers+and+Acquisitions/Ipsen+acquires+Memo+Therapeutics%2C+adding+kidney+transplant+drug/26796982.html <p>Ipsen (Euronext: IPN; ADR: IPSEY) has completed its acquisition of Memo Therapeutics AG, a late-stage biotech company developing potravitug, a monoclonal antibody targeting BK polyomavirus reactivation in kidney transplant recipients, according to a press release from the Paris-based company.</p> <p>Potravitug is described as a monoclonal antibody targeting BK polyomavirus (BKPyV) reactivation in kidney transplant recipients. The drug has been evaluated in the Phase II SAFE KIDNEY II trial, which the company says is the largest placebo-controlled study conducted in this patient population. The trial showed an anti-viral response and resolution of BKPyV-associated nephropathy.</p> <p>BKPyV is a virus that can reactivate in immunocompromised http://www.streetinsider.com/Mergers+and+Acquisitions/Ipsen+acquires+Memo+Therapeutics%2C+adding+kidney+transplant+drug/26796982.html Wed, 22 Jul 2026 01:00:14 -0400 A.00204076 A.18335591 A.31979641 IPN IPSEY O.00323532 O.00374663 O.04960887 O.14731247 http://www.streetinsider.com/Mergers+and+Acquisitions/Ipsen+acquires+Memo+Therapeutics%2C+adding+kidney+transplant+drug/26796982.html <p>Ipsen (Euronext: IPN; ADR: IPSEY) has completed its acquisition of Memo Therapeutics AG, a late-stage biotech company developing potravitug, a monoclonal antibody targeting BK polyomavirus reactivation in kidney transplant recipients, according to a press release from the Paris-based company.</p> <p>Potravitug is described as a monoclonal antibody targeting BK polyomavirus (BKPyV) reactivation in kidney transplant recipients. The drug has been evaluated in the Phase II SAFE KIDNEY II trial, which the company says is the largest placebo-controlled study conducted in this patient population. The trial showed an anti-viral response and resolution of BKPyV-associated nephropathy.</p> <p>BKPyV is a virus that can reactivate in immunocompromised http://www.streetinsider.com/Mergers+and+Acquisitions/Ipsen+acquires+Memo+Therapeutics%2C+adding+kidney+transplant+drug/26796982.html Wed, 22 Jul 2026 01:00:14 -0400 A.00204076 A.18335591 A.31979641 IPN IPSEY O.00323532 O.00374663 O.04960887 O.14731247 http://www.streetinsider.com/Mergers+and+Acquisitions/Ipsen+acquires+Memo+Therapeutics%2C+adding+kidney+transplant+drug/26796982.html <p>Ipsen (Euronext: IPN; ADR: IPSEY) has completed its acquisition of Memo Therapeutics AG, a late-stage biotech company developing potravitug, a monoclonal antibody targeting BK polyomavirus reactivation in kidney transplant recipients, according to a press release from the Paris-based company.</p> <p>Potravitug is described as a monoclonal antibody targeting BK polyomavirus (BKPyV) reactivation in kidney transplant recipients. The drug has been evaluated in the Phase II SAFE KIDNEY II trial, which the company says is the largest placebo-controlled study conducted in this patient population. The trial showed an anti-viral response and resolution of BKPyV-associated nephropathy.</p> <p>BKPyV is a virus that can reactivate in immunocompromised http://www.streetinsider.com/Mergers+and+Acquisitions/Ipsen+acquires+Memo+Therapeutics%2C+adding+kidney+transplant+drug/26796982.html Wed, 22 Jul 2026 01:00:14 -0400 A.00204076 A.18335591 A.31979641 IPN IPSEY O.00323532 O.00374663 O.04960887 O.14731247